FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791043379> ?p ?o ?g. }

• W2791043379 endingPage "1210" @default.
• W2791043379 startingPage "1201" @default.
• W2791043379 abstract "Programmed cell death-1/ligand (PD-1/PD-L1) interaction negatively regulates T cell activity. PD-L1 expression in tumor cells, antigen-presenting cells, and lymphocytes of the tumor microenvironment is associated with response to treatment with PD-1/PD-L1 inhibitors, but there is still debate on the cutoff value that correlates with responders. In uveal melanoma (UM), 40% of patients will develop liver metastases and, amongst them, 90% will succumb to their disease. The aim of this study was to analyze PD-L1 expression as a prognostic marker and as a possible therapeutic target for UM. Sixty-seven enucleated eyes from UM patients with relevant clinical information were analyzed. Univariate and multivariate analysis were used to evaluate association of PD-L1 with survival. PD-L1 expression was positive relatively to tumor cells, immune cells, and the tumor and tumor-infiltrating immune cell group scoring in 46, 34 and 55% of the cases, respectively. On univariate analysis, tumor cells and the tumor and tumor-infiltrating immune cell group PD-L1 expression was associated with a longer metastasis-free survival (P = 0.04 and P = 0.007). However, on multivariate analysis, only the tumor and tumor-infiltrating immune cell group positivity was associated with longer metastasis-free survival (P = 0.01). Furthermore, tumor cells and the tumor and tumor-infiltrating immune cell group PD-L1 expression was associated with decreased tumor-infiltrating lymphocytes (P = 0.02). PD-L1, when expressed in uveal melanoma, is associated with better patient outcome and decreased tumor-infiltrating lymphocytes. These results support the consideration of anti-PD-1/PD-L1 therapy in uveal melanoma. To determine the best cutoff value, further studies from patients enrolled in clinical trials treated with PD-1/PD-L1 inhibitors are necessary." @default.
• W2791043379 created "2018-03-29" @default.
• W2791043379 creator A5007201944 @default.
• W2791043379 creator A5017259563 @default.
• W2791043379 creator A5019454660 @default.
• W2791043379 creator A5019983656 @default.
• W2791043379 creator A5020232745 @default.
• W2791043379 creator A5029205479 @default.
• W2791043379 creator A5029576539 @default.
• W2791043379 creator A5043514225 @default.
• W2791043379 creator A5056443663 @default.
• W2791043379 creator A5083462162 @default.
• W2791043379 creator A5084364691 @default.
• W2791043379 date "2018-08-01" @default.
• W2791043379 modified "2023-10-16" @default.
• W2791043379 title "Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma" @default.
• W2791043379 cites W1889335134 @default.
• W2791043379 cites W1967790688 @default.
• W2791043379 cites W1976244358 @default.
• W2791043379 cites W1989681063 @default.
• W2791043379 cites W1995712355 @default.
• W2791043379 cites W2009503910 @default.
• W2791043379 cites W2016983859 @default.
• W2791043379 cites W2022465587 @default.
• W2791043379 cites W2030106234 @default.
• W2791043379 cites W2033672531 @default.
• W2791043379 cites W2037915750 @default.
• W2791043379 cites W2041915101 @default.
• W2791043379 cites W2042101061 @default.
• W2791043379 cites W2056737202 @default.
• W2791043379 cites W2065121081 @default.
• W2791043379 cites W2072653487 @default.
• W2791043379 cites W2107484016 @default.
• W2791043379 cites W2109485845 @default.
• W2791043379 cites W2111225997 @default.
• W2791043379 cites W2121314233 @default.
• W2791043379 cites W2126209042 @default.
• W2791043379 cites W2127644935 @default.
• W2791043379 cites W2130030995 @default.
• W2791043379 cites W2159170430 @default.
• W2791043379 cites W2160706109 @default.
• W2791043379 cites W2160834915 @default.
• W2791043379 cites W2164842455 @default.
• W2791043379 cites W2166662937 @default.
• W2791043379 cites W2187430385 @default.
• W2791043379 cites W2281321365 @default.
• W2791043379 cites W2287768841 @default.
• W2791043379 cites W2289528730 @default.
• W2791043379 cites W2293531514 @default.
• W2791043379 cites W2302088846 @default.
• W2791043379 cites W2340166080 @default.
• W2791043379 cites W2346535379 @default.
• W2791043379 cites W2409195327 @default.
• W2791043379 cites W2501104052 @default.
• W2791043379 cites W2509486054 @default.
• W2791043379 cites W2515516401 @default.
• W2791043379 cites W2527129822 @default.
• W2791043379 cites W2557730509 @default.
• W2791043379 cites W2559382297 @default.
• W2791043379 cites W2562156357 @default.
• W2791043379 cites W2606764737 @default.
• W2791043379 cites W2611893941 @default.
• W2791043379 cites W2745448165 @default.
• W2791043379 cites W4237107236 @default.
• W2791043379 doi "https://doi.org/10.1038/s41379-018-0043-5" @default.
• W2791043379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29581543" @default.
• W2791043379 hasPublicationYear "2018" @default.
• W2791043379 type Work @default.
• W2791043379 sameAs 2791043379 @default.
• W2791043379 citedByCount "19" @default.
• W2791043379 countsByYear W27910433792019 @default.
• W2791043379 countsByYear W27910433792020 @default.
• W2791043379 countsByYear W27910433792021 @default.
• W2791043379 countsByYear W27910433792022 @default.
• W2791043379 countsByYear W27910433792023 @default.
• W2791043379 crossrefType "journal-article" @default.
• W2791043379 hasAuthorship W2791043379A5007201944 @default.
• W2791043379 hasAuthorship W2791043379A5017259563 @default.
• W2791043379 hasAuthorship W2791043379A5019454660 @default.
• W2791043379 hasAuthorship W2791043379A5019983656 @default.
• W2791043379 hasAuthorship W2791043379A5020232745 @default.
• W2791043379 hasAuthorship W2791043379A5029205479 @default.
• W2791043379 hasAuthorship W2791043379A5029576539 @default.
• W2791043379 hasAuthorship W2791043379A5043514225 @default.
• W2791043379 hasAuthorship W2791043379A5056443663 @default.
• W2791043379 hasAuthorship W2791043379A5083462162 @default.
• W2791043379 hasAuthorship W2791043379A5084364691 @default.
• W2791043379 hasBestOaLocation W27910433791 @default.
• W2791043379 hasConcept C121608353 @default.
• W2791043379 hasConcept C126322002 @default.
• W2791043379 hasConcept C142724271 @default.
• W2791043379 hasConcept C144301174 @default.
• W2791043379 hasConcept C147483822 @default.
• W2791043379 hasConcept C1491633281 @default.
• W2791043379 hasConcept C192638826 @default.
• W2791043379 hasConcept C203014093 @default.
• W2791043379 hasConcept C2776090121 @default.
• W2791043379 hasConcept C2776107976 @default.

• next